AstraZeneca recently set the price of its new Brilique blood thinner, which it hopes will become its next blockbuster drug, at €1.69 ($2.38) per pill in Germany. Whether it will be allowed to maintain that price in Europe’s largest drug market remains to be seen. You see Europe has a new pricing law that requires pharmaceutical companies to prove not just that a drug works but that it is actually worth more than older therapies. If a drug maker can’t convince German regulators that its compound has greater efficacy or additional benefits, then it cannot charge more than rival medicines already on the market. The same or similar regulations are in place throughout Europe. (the source for this information is Businessweek June 6, 2011 edition)
Compare this justification procedure with laws in the United States. There are no such laws in this country. The government does not regulate pricing on any product or service with the exception of some insurance (California law demands justification of insurance rates for auto coverage).
Rather than not develop new drugs, the pharmaceutical companies have developed economic reviews of their products and plan to provide life impact justifications. The review of the data will delay the initial release of new products but will help to control the cost of medical care.
A new study showing that the chemotherapy drug Vemurafenib can prolong the lives of people with malignant melanoma — the especially aggressive and dangerous form of skin cancer that kills about 8,700 Americans each year — has rightfully lifted the spirits of doctors and patients alike. It was a feature item recently on ABC World News. However the Los Angeles Times reports interviewing Tim Turnham, executive director of the Melanoma Research Foundation. He told the Times “There’s been a lot of hype in the news, but this is not a home run. It’s a really solid single.” An expensive single, at that. Vemurafenib will likely cost tens of thousands of dollars per year. (Turnham’s off-the-cuff guess is $50,000.)
Should Medicare or any insurance company pay for high-priced specialized care? If it’s for your mother, your father, your brother the answer is YES. Sadly society cannot afford everything. Why can’t Medicare negotiate drug costs? Perhaps capitalism is not always the right answer.
